Aarti Drugs Limited announced commencement of production of Dermatology Product at new facility at Tarapur, Maharashtra on 30th January 2024. The new facility at Tarapur, which is located adjacent to its existing manufacturing units, is equipped with cutting-edge technology and adhering to the highest industry standards, has commenced production of dermatology product from 30th January 2024 with floor area of 40,000 sq ft. This strategic expansion aligns with company's vision to strengthen its presence in the skincare segment and contribute to the advancement of healthcare.

The dermatology product portfolio encompasses a wide range of formulations designed to address various dermatological conditions, including but not limited to, dermatitis, psoriasis, acne, and eczema. The company's commitment to research and development ensures the continuous evolution of its product offerings to meet the dynamic needs of healthcare professionals and patients. Total Investment requirement will be ~INR 1,500 million to INR 2,000 million to complete setting up this facility partially financed through term loan and internal accruals.

This facility will have total operational capacity of 24,000 MTPA. Product manufactured will cater to domestic demand at first and with growing opportunities, company shall extend its reach to export markets as well.